BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1845 related articles for article (PubMed ID: 34027555)

  • 21. A novel cuproptosis-related lncRNA signature predicts the prognosis and immunotherapy for hepatocellular carcinoma.
    Liu Y; Jiang J
    Cancer Biomark; 2023; 37(1):13-26. PubMed ID: 37005878
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of hepatocellular carcinoma prognostic markers based on 10-immune gene signature.
    Zhao K; Xu L; Li F; Ao J; Jiang G; Shi R; Chen F; Luo Q
    Biosci Rep; 2020 Aug; 40(8):. PubMed ID: 32789471
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comprehensive analysis of tumor immune microenvironment and prognosis of m6A-related lncRNAs in gastric cancer.
    Wang Y; Zhu GQ; Tian D; Zhou CW; Li N; Feng Y; Zeng MS
    BMC Cancer; 2022 Mar; 22(1):316. PubMed ID: 35331183
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Implications of m6A-associated snRNAs in the prognosis and immunotherapeutic responses of hepatocellular carcinoma.
    Zhang C; Zhang W; Shui Y; Li P; Tian Z; Duan S; Wei Q
    Front Immunol; 2022; 13():1001506. PubMed ID: 36405741
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comprehensive analysis of cuproptosis-related lncRNAs in immune infiltration and prognosis in hepatocellular carcinoma.
    Liu C; Wu S; Lai L; Liu J; Guo Z; Ye Z; Chen X
    BMC Bioinformatics; 2023 Jan; 24(1):4. PubMed ID: 36597032
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A prognostic signature based on the expression profile of the ferroptosis-related long non-coding RNAs in hepatocellular carcinoma.
    Lin X; Yang S
    Adv Clin Exp Med; 2022 Oct; 31(10):1099-1109. PubMed ID: 35581934
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression and prognostic signatures of m6A-related lncRNAs in hepatocellular carcinoma.
    Hao K; Li J; Zhang Y; Zhao W; Chen X; Xu J; Tian Y; Li X; Fen J; He X
    J Cancer Res Clin Oncol; 2023 Jul; 149(8):4429-4441. PubMed ID: 36121511
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Construction of a novel immune-related lncRNA signature and its potential to predict the immune status of patients with hepatocellular carcinoma.
    Deng M; Lin JB; Zhao RC; Li SH; Lin WP; Zou JW; Wei W; Guo RP
    BMC Cancer; 2021 Dec; 21(1):1347. PubMed ID: 34923955
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of a novel m6A-related lncRNA pair signature for predicting the prognosis of gastric cancer patients.
    Wang JM; Li X; Yang P; Geng WB; Wang XY
    BMC Gastroenterol; 2022 Feb; 22(1):76. PubMed ID: 35189810
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long non-coding RNA-based signature for predicting prognosis of hepatocellular carcinoma.
    Cao J; Wu L; Lei X; Shi K; Shi L; Shi Y
    Bioengineered; 2021 Dec; 12(1):673-681. PubMed ID: 33622186
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anoikis-related lncRNA signature predicts prognosis and is associated with immune infiltration in hepatocellular carcinoma.
    Zhu J; Zhao W; Yang J; Liu C; Wang Y; Zhao H
    Anticancer Drugs; 2024 Jun; 35(5):466-480. PubMed ID: 38507233
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An effective N6-methyladenosine-related long non-coding RNA prognostic signature for predicting the prognosis of patients with bladder cancer.
    Ma T; Wang X; Meng L; Liu X; Wang J; Zhang W; Tian Z; Zhang Y
    BMC Cancer; 2021 Nov; 21(1):1256. PubMed ID: 34802433
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An immune-related gene signature for predicting survival and immunotherapy efficacy in hepatocellular carcinoma.
    Dai Y; Qiang W; Lin K; Gui Y; Lan X; Wang D
    Cancer Immunol Immunother; 2021 Apr; 70(4):967-979. PubMed ID: 33089373
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oncogenic signaling pathway-related long non-coding RNAs for predicting prognosis and immunotherapy response in breast cancer.
    Li H; Liu H; Hao Q; Liu X; Yao Y; Cao M
    Front Immunol; 2022; 13():891175. PubMed ID: 35990668
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development of a novel immune-related lncRNA prognostic signature for patients with hepatocellular carcinoma.
    Li R; Jin C; Zhao W; Liang R; Xiong H
    BMC Gastroenterol; 2022 Nov; 22(1):450. PubMed ID: 36344926
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic Value of an Immune Long Non-Coding RNA Signature in Liver Hepatocellular Carcinoma.
    Kong R; Wang N; Zhou CL; Lu J
    J Microbiol Biotechnol; 2024 Apr; 34(4):958-968. PubMed ID: 38494878
    [TBL] [Abstract][Full Text] [Related]  

  • 37. N6-methylandenosine-related lncRNAs play an important role in the prognosis and immune microenvironment of pancreatic ductal adenocarcinoma.
    Hu Y; Chen Y
    Sci Rep; 2021 Sep; 11(1):17844. PubMed ID: 34497315
    [TBL] [Abstract][Full Text] [Related]  

  • 38. m6A regulator-mediated methylation modification patterns and tumor microenvironment infiltration characterization in hepatocellular carcinoma.
    Huang X; Qiu Z; Li L; Chen B; Huang P
    Aging (Albany NY); 2021 Aug; 13(16):20698-20715. PubMed ID: 34461607
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma.
    Guo W; Tan F; Huai Q; Wang Z; Shao F; Zhang G; Yang Z; Li R; Xue Q; Gao S; He J
    Front Immunol; 2021; 12():669750. PubMed ID: 34054840
    [TBL] [Abstract][Full Text] [Related]  

  • 40. N6-methyladenosine (m6A) RNA methylation regulator SNRPC is a prognostic biomarker and is correlated with immunotherapy in hepatocellular carcinoma.
    Cai J; Zhou M; Xu J
    World J Surg Oncol; 2021 Aug; 19(1):241. PubMed ID: 34389000
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 93.